Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party presidential primary candidate Vivek Ramaswamy[1] in October 2014 as a wholly owned subsidiary of Roivant Sciences, which was itself founded in May 2014.[2]
History
In December 2014, Axovant acquired rights to the drug intepirdine from GlaxoSmithKline.[3] Intepirdine is a potential add-on treatment to donepezil for patients with Alzheimer's disease and patients with dementia with Lewy bodies.[1]